Übersetzung für "Favorable safety profile" in Deutsch

A generally favorable safety profile was observed for both VEGF Trap-Eye and ranibizumab.

The study also showed that riociguat was well tolerated and had a favorable safety profile.

Furthermore, the final analysis confirmed the favorable safety profile and the mode of action of lefitolimod.

The data confirm the favorable safety profile of lefitolimod, also in combination with ipilimumab.

The results showed that ODM-201 provided disease suppression and had a favorable safety profile.

In the section "Adverse Effects" the text says: "Cannabinoids have a favorable drug safety profile.

The primary endpoint did not reach statistical significance, while the favorable safety profile of riociguat was confirmed.

Netarsudil dosed twice daily provided slightly larger IOP reductions, but had a less favorable safety profile as reflected in a higher rate and increased severity of ocular adverse reactions.

In addition, toxicity studies using various in vitro and in silico tools revealed a favorable preclinical safety profile for this TCR.

IMVAMUNE has been given to more than 7,800 subjects in 21 clinical studies, including two Phase 3 studies that have supported a favorable safety profile and efficacy in comparison to replicating smallpox vaccines.

These data, combined with the favorable safety profile of lefitolimod which was again confirmed, are another important stepping stone in the development strategy for lefitolimod in HIV.

Bayer is convinced that neonicotinoids are user-safe insecticides with a favorable environmental safety profile, and are not dangerous to bees when used according to label instructions.

Importantly, besides confirming the favorable safety profile, we see clear hints for beneficial TME-modulating effects in patients.

Jason Loveridge, Ph.D., CEO of 4SC: "Taking note of the favorable safety profile and first signs of clinical efficacy from the combination of domatinostat and pembrolizumab in this very hard to treat, anti-PD-1-refractory patient population is exciting and hugely encouraging.

Data so far indicate that remimazolam has a rapid onset and offset of action combined with a favorable cardio-respiratory safety profile.

We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile.

Although the study did not show the expected superiority of lefitolimod as a single-agent therapeutic in comparison with standard therapy, the confirmation of the favorable safety and tolerability profile and of the once again proven activation of the immune system provide strong support for the strategic decision to focus future development work exclusively on combination approaches with lefitolimod and EnanDIM(R).

These data together with the favorable safety profile of lefitolimod now confirmed also in HIV, form the basis for our future development strategy for lefitolimod in combination therapies.

The key question is whether Ozanimod can demonstrate the same efficacy and a more favorable safety profile than Gilenya, a competing product from Novartis that has already been approved.

Given its mode of action and confirmed favorable safety profile, lefitolimod is being used as combination partner in anti-cancer and anti-HIV immunotherapies.

The available data supports the assumption that lefitolimod and EnanDIM(R) successfully create a beneficial modulation of the tumor microenvironment (TME) and, together with a favorable safety profile, could potentially be perfect partners for immuno-oncological combination approaches.

The available data supports the assumption that lefitolimod and EnanDIM(R) successfully generate a beneficial modulation of the tumor microenvironment (TME) and, together with a favorable safety profile, could potentially be perfect partners for immuno-oncological combination approaches.

These data together with the favorable safety profile of lefitolimod now confirmed also in HIV form the basis for our future development strategy for lefitolimod in combination therapies.

In particular, the data showed that maintenance therapy with lefitolimod in patients with extensive stage small-cell lung cancer (ES-SCLC) has a favorable safety profile, presented with the expected immunological responses and positive overall survival outcomes in two predefined patient groups.

All other dose groups of VEGF Trap-Eye in the VIEW1 study and all dose groups in the VIEW 2 study were not statistically different from ranibizumab in this secondary endpoint.A generally favorable safety profile was observed for both VEGF Trap-Eye and ranibizumab.